The perspectives of biologics in the treatment of chronic rhinosinusitis with nasal polyps.
10.13201/j.issn.2096-7993.2023.11.001
- Author:
Luo ZHANG
1
Author Information
1. Department of Otolaryngology Head and Neck Surgery，Beijing TongRen Hospital，Capital Medical University，Beijing，100730，China.
- Publication Type:Journal Article
- Keywords:
biologics;
chronic rhinosinusitis with nasal polyps;
treatment
- MeSH:
Humans;
Biological Products/therapeutic use*;
Rhinitis/drug therapy*;
Nasal Polyps/drug therapy*;
Sinusitis/drug therapy*;
Cytokines;
Chronic Disease
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2023;37(11):853-855
- CountryChina
- Language:Chinese
-
Abstract:
Chronic rhinosinusitis with nasal polyps （CRSwNP） remains the most difficult-to-treat subtype in the world. Biologics have shown positive results, especially in reducing nasal polyp size and improving patient-reported outcomes. The development of biologics has the potential to fulfill the unmet medical needs of treatment.
